Hi Curiouser27. The company is tracking or exceeding targeted benchmarks for its current stage of development, with R&D a significant outgoing as would be expected. The US expenses have now been virtually extinguished so the cash burn will reduce accordingly. If you look back you'll find the coy has imho always been very prudent with its expenses, looking for and taking opportunities to eliminate capital expenses not necessary for prosecution of its vision.
You'll also have noted the large cash injections from Merck over the years, so although its a long time between drinks, the current portfolio of drugs under development is imho very promising, Merck seem to agree.
You will need patience with this stock though, no overnight success story here.
BNO Price at posting:
48.0¢ Sentiment: Hold Disclosure: Held
